Join the Oncology Voice Network. Join for Free
Illuminating science for patients and healthcare professionals through plain language podcasts
patient engagement in podcasts medical education podcasts MedComms webinars scientific communication for patients expert-led

Illuminating science for patients and healthcare professionals through plain language podcasts


Share This Article


Summary

Note this is a video recording of an online meeting conducted using the Zoom.us platform. Inevitably such recordings suffer a little in terms of their production values because of the internet connectivity and quality of webcams. Despite that, they allow us to provide additional valuable insights in to the MedComms business and we can involve a wider range of speakers who can participate from the comfort of their own desks, wherever in the world they are.

Expert-led podcasts summarising the latest clinical data and expert opinion, including discussions of data presented at scientific congresses, have been published by journals as peer-reviewed, citable publications. They have also been published as part of IME (independent medical education) programmes. But is it possible to create these podcasts in plain language, with both patient and healthcare professional authors? If we are trying to educate a broad audience of stakeholders (from lay audiences to highly specialised clinicians) with scientific content, can patients be podcast authors and create content with maximum impact? The answer to these key questions is yes!

Join Caroline Halford from Springer Healthcare, Niamh Clarke from Adis, and Catherine Elliott and Simon Stones from Envision Pharma Group to hear about their experience of creating plain language podcasts and the potential for using these types of initiative to make scientific information more impactful, and more accessible to a wider audience.

And we answer questions from the audience.

It should be of interest to anyone who is working in and around MedComms, publications, medical education, or has an interest in patient engagement.

Recorded 09 November 2022 as a MedComms Networking webinar. Produced by NetworkPharma.tv

Find out more about Springer Healthcare and Adis journals at https://springerhealthcare.com/

Find out more about Envision Pharma Group at https://www.envisionpharmagroup.com/

Further information:

Patient and Healthcare Professional Perspectives from ESMO 2021 on Bladder and Kidney Cancer: A Podcast
See https://link.springer.com/article/10.1007/s40487-022-00185-5

CME patient podcasts from Springer Healthcare IME,
See https://fop.ime.springerhealthcare.com/insights/#podcasts

Click for Source
patient engagement in podcasts, medical education podcasts, MedComms webinars, scientific communication for patients, expert-led

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Article
Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms
OVN Avatar Angus Liu

Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms

Article
Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology
OVN Avatar Yan Ji, Jin Y. Jin, David M. Hyman, Geoffrey Kim and Ajit Suri

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology

Explore OVN